Oncosil  is a single-use internal radiation device that delivers a dose of predetermined beta radiation directly into pancreatic cancerous tissue. The radiation only goes to the cancer cells and doesn't affect the surrounding tissue, such as other vital organs located nearby. 

The OncoSil device is branded as one of the most innovative ways of treating pancreatic cancer. This has been driven by an experienced and talented team, who assisted with local regulatory approvals and ethics approvals and engaged in site training, with twelve (12) hospitals now fully trained to administer the treatment of the Oncosil device in ten (10) countries. Beyond the first treatments in Italy and Spain, treatment has continued to expand in Spain where it won a tender from Las Palmas Hospital in the Canary Islands, Spain, valued at €220K (A$361k). 

In addition to a strong expansion across the world (38 countries), it is gearing up to begin the production of the Oncosil device, potentially improving the certainty of its supply chain and accelerating its global expansion. Below, we provide an illustration of the team and their background/achievements. 

Nigel Lange - Chief Executive Officer and Managing Director

Nigel joined the Company in May 2020 as the Europe, Middle East, and Africa (‘EMEA’) President and brings with him over 30 years of experience in the medical devices industry. Since 2003, Nigel has held various leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer, which sold for 1.9 billion Australian dollars, under Lange’s leadership. From 2003, Nigel served as Chief Executive Officer of Sirtex’s European business, responsible for establishing their brachytherapy device in over 300 centers across Europe and the Middle East. 

Since 2017, Nigel has served as Group Chief Commercial Officer where he was responsible for all commercial aspects of the global business. During this time, Nigel has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific.

Otto Buttula - Non-Executive Chairman

Buttula has had extensive experience and success in investment research, funds management, information, and biotechnologies and has held directorships in several public companies. Buttula’s executive experience includes cofounder, CEO and Managing Director of IWL Ltd, an online financial services company that was listed on the ASX in 1999. The company grew from a market capitalisation of $48 million at listing before a takeover in 2007 by Commonwealth Bank of Australia for $373 million. Buttula founded and managed Investors Mutual and was a co-founder and director of Lonsdale Securities Limited. Following his completion of executive duties, Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Ltd and led the acquisition of HUB24 Limited (ASX: HUB). 

More recently, he served on the Board as a Non-Executive Director and Head of Audit and Risk at Imugene Ltd (ASX: IMU) between 2014 and 2016 and currently is the Executive Chairman of Rhythm Biosciences Ltd (ASX: RHY) and Non-Executive Chairman of HITIQ Ltd (ASX: HIQ). His significant experience in biotech and finance makes him an ideal candidate to support the commercialisation of Oncosil abroad. 

Brian Leedman - Non-Executive Director

Leedman is a marketing and investor relations professional with over 15 years of experience in the biotechnology industry. Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Limited to form ResApp Health Limited where Leedman was the Executive Director of Corporate Affairs. ResApp Health was acquired by Pfizer (Aust) Limited in 2022.  

Leedman is an experienced public company director having formerly been the Chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited, and was a Director of Alcidion Corporation Limited. Before ResApp, Leedman co-founded OncoSil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited). Leedman previously served for ten years as Vice President of Investor Relations for pSivida Corp. Limited, which was listed on the ASX, Frankfurt, and NASDAQ. He was formerly the WA Chairman of AusBiotech, the association of biotechnology companies in Australia.

Dr Gabriel Liberatore - Non-Executive Director

Dr. Liberatore is an experienced biopharmaceutical executive with over 25 years of experience in senior Business Development, R&D, and strategic operational management positions including taking products to market. 

Until recently, he was the Group Chief Operating Officer at Telix Pharmaceuticals (ASX: TLX) a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Currently, Dr. Liberatore is a Strategic Advisor to GlyTherix Ltd, an Australian immuno-oncology company specializing in developing antibody radiopharmaceuticals for solid tumors.

Douglas Cubbin - Non-Executive Director

Cubbin is an experienced biopharmaceutical executive with over 30 years of experience in senior executive, CFO, Director, and Chair roles, across varied industries. During his tenure as Group Chief Financial Officer at Telix Pharmaceuticals Limited (ASX: TLX), a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, he was a key member of the team which completed the IPO, raised $270 million in capital and grew the business to a multi-billion dollar market capitalisation. Cubbin has also served as Chairman of various boards, including the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine. 

Oncosil has a talented and experienced team, led by Nigel Lange who has created and sold a highly successful biotech firm. Due to the technical nature of the product, Oncosil will only excel under a skilled management team that understands the market and can support the successful rollout of the product. Revenues have grown over the last three years and the adoption of the Oncosil device has increased, expanding commercialisation on a global scale. 

The capital raise will allow it to begin manufacturing the Oncosil device, accelerate control trials, and improve rollout across more hospitals across the world. Let’s not forget that a major insurer in the UK is now approving reimbursement for the Oncosil device treatment of pancreatic cancer.